S&P 500   4,080.11
DOW   34,589.77
QQQ   293.36
The AP Interview: IMF head urges China to end mass lockdowns
A $226B Copper Spending Jackpot (Ad)
Santa Claus Rally? Here’s What Needs to Happen
3 Dividend Growers With Good 2023 Growth Prospects
A $226B Copper Spending Jackpot (Ad)
Build Your Quality of Life by Investing in Your Lifestyle
Cosmos Holdings May be a Long-Term Buy with Short-Term Risk
A $226B Copper Spending Jackpot (Ad)
Dark Clouds Are Gathering For Cloud Stocks 
Hormel: Is This The Time To Buy?
S&P 500   4,080.11
DOW   34,589.77
QQQ   293.36
The AP Interview: IMF head urges China to end mass lockdowns
A $226B Copper Spending Jackpot (Ad)
Santa Claus Rally? Here’s What Needs to Happen
3 Dividend Growers With Good 2023 Growth Prospects
A $226B Copper Spending Jackpot (Ad)
Build Your Quality of Life by Investing in Your Lifestyle
Cosmos Holdings May be a Long-Term Buy with Short-Term Risk
A $226B Copper Spending Jackpot (Ad)
Dark Clouds Are Gathering For Cloud Stocks 
Hormel: Is This The Time To Buy?
S&P 500   4,080.11
DOW   34,589.77
QQQ   293.36
The AP Interview: IMF head urges China to end mass lockdowns
A $226B Copper Spending Jackpot (Ad)
Santa Claus Rally? Here’s What Needs to Happen
3 Dividend Growers With Good 2023 Growth Prospects
A $226B Copper Spending Jackpot (Ad)
Build Your Quality of Life by Investing in Your Lifestyle
Cosmos Holdings May be a Long-Term Buy with Short-Term Risk
A $226B Copper Spending Jackpot (Ad)
Dark Clouds Are Gathering For Cloud Stocks 
Hormel: Is This The Time To Buy?
S&P 500   4,080.11
DOW   34,589.77
QQQ   293.36
The AP Interview: IMF head urges China to end mass lockdowns
A $226B Copper Spending Jackpot (Ad)
Santa Claus Rally? Here’s What Needs to Happen
3 Dividend Growers With Good 2023 Growth Prospects
A $226B Copper Spending Jackpot (Ad)
Build Your Quality of Life by Investing in Your Lifestyle
Cosmos Holdings May be a Long-Term Buy with Short-Term Risk
A $226B Copper Spending Jackpot (Ad)
Dark Clouds Are Gathering For Cloud Stocks 
Hormel: Is This The Time To Buy?
NASDAQ:ATXI

Avenue Therapeutics - ATXI Competitors

$1.34
+0.03 (+2.29%)
(As of 11/30/2022 12:00 AM ET)
Add
Compare
Today's Range
$1.24
$1.36
50-Day Range
$1.31
$67.50
52-Week Range
$1.24
$26.85
Volume
153,493 shs
Average Volume
615,813 shs
Market Capitalization
$6.41 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

ATXI vs. MTP, ATHX, AMPE, CPHI, NEPT, TENX, STAB, XBIO, ENVB, and CFRX

Should you be buying Avenue Therapeutics stock or one of its competitors? The main competitors of Avenue Therapeutics include Midatech Pharma (MTP), Athersys (ATHX), Ampio Pharmaceuticals (AMPE), China Pharma (CPHI), Neptune Wellness Solutions (NEPT), Tenax Therapeutics (TENX), Statera Biopharma (STAB), Xenetic Biosciences (XBIO), Enveric Biosciences (ENVB), and ContraFect (CFRX). These companies are all part of the "pharmaceutical preparations" industry.

Avenue Therapeutics vs.

Midatech Pharma (NASDAQ:MTP) and Avenue Therapeutics (NASDAQ:ATXI) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, institutional ownership, earnings, valuation, community ranking, profitability, risk and dividends.

In the previous week, Avenue Therapeutics had 1 more articles in the media than Midatech Pharma. MarketBeat recorded 2 mentions for Avenue Therapeutics and 1 mentions for Midatech Pharma. Midatech Pharma's average media sentiment score of 1.87 beat Avenue Therapeutics' score of 1.44 indicating that Midatech Pharma is being referred to more favorably in the media.

Company Overall Sentiment
Midatech Pharma Very Positive
Avenue Therapeutics Positive

Midatech Pharma has a beta of 2.38, indicating that its share price is 138% more volatile than the S&P 500. Comparatively, Avenue Therapeutics has a beta of -0.57, indicating that its share price is 157% less volatile than the S&P 500.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Midatech Pharma
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A
Avenue Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A

Avenue Therapeutics received 10 more outperform votes than Midatech Pharma when rated by MarketBeat users. However, 75.00% of users gave Midatech Pharma an outperform vote while only 59.92% of users gave Avenue Therapeutics an outperform vote.

CompanyUnderperformOutperform
Midatech PharmaOutperform Votes
135
75.00%
Underperform Votes
45
25.00%
Avenue TherapeuticsOutperform Votes
145
59.92%
Underperform Votes
97
40.08%

Midatech Pharma's return on equity of 0.00% beat Avenue Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Midatech Pharma N/A N/A N/A
Avenue Therapeutics N/A -390.02% -268.94%

Avenue Therapeutics has lower revenue, but higher earnings than Midatech Pharma.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Midatech Pharma$800 thousand7.83-$7.51 millionN/AN/A
Avenue TherapeuticsN/AN/A-$3.73 million-$3.75-0.36

3.4% of Midatech Pharma shares are held by institutional investors. Comparatively, 10.9% of Avenue Therapeutics shares are held by institutional investors. 0.8% of Avenue Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Midatech Pharma beats Avenue Therapeutics on 6 of the 11 factors compared between the two stocks.


New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ATXI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ATXI vs. The Competition

MetricAvenue TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$6.26M$5.86B$4.63B$5.41B
Dividend YieldN/A2.38%7.18%3.95%
P/E Ratio-0.363.7396.5011.40
Price / SalesN/A399.923,222.7890.97
Price / CashN/A21.1422.3483.18
Price / Book-134.004.915.986.57
Net Income-$3.73M$184.33M$163.06M$236.57M
7 Day Performance-8.22%1.27%0.99%0.96%
1 Month Performance-42.98%5.17%4.71%3.47%
1 Year Performance-93.28%-35.15%-28.38%-23.94%

Avenue Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
MTP
Midatech Pharma
0 of 5 stars
$1.59
+3.9%
N/A-78.2%$6.27M$800,000.000.0018Positive News
Gap Up
ATHX
Athersys
1.7012 of 5 stars
$0.60
-1.7%
$6.25
+950.1%
-97.8%$6.55M$5.51M-0.08104Short Interest ↓
Positive News
AMPE
Ampio Pharmaceuticals
0 of 5 stars
$0.41
+2.5%
N/AN/A$6.23MN/A-0.22N/AAnalyst Report
Gap Down
CPHI
China Pharma
0 of 5 stars
$0.12
flat
N/AN/A$6.23M$9.64M-1.51237Analyst Report
News Coverage
Gap Up
High Trading Volume
NEPT
Neptune Wellness Solutions
1.4986 of 5 stars
$0.73
-3.9%
N/A-95.8%$6.22M$48.80M-0.0658Positive News
Gap Up
TENX
Tenax Therapeutics
1.629 of 5 stars
$0.15
+7.2%
N/A-88.4%$6.62MN/A0.008Analyst Report
Short Interest ↑
News Coverage
Gap Up
High Trading Volume
STAB
Statera Biopharma
0 of 5 stars
$0.13
-13.8%
N/A-95.7%$6.66M$1.49M0.0018Short Interest ↓
Positive News
Gap Up
XBIO
Xenetic Biosciences
2.1401 of 5 stars
$0.44
+4.8%
$4.00
+809.1%
-69.0%$6.67M$1.16M0.004Positive News
Gap Up
ENVB
Enveric Biosciences
2.1138 of 5 stars
$2.87
+0.7%
$43.75
+1,424.4%
-95.6%$5.96M$39.92M-0.032Short Interest ↓
Positive News
Gap Up
CFRX
ContraFect
2.3236 of 5 stars
$0.18
+20.5%
$3.00
+1,598.8%
-94.8%$6.95MN/A-0.1238Analyst Report
Short Interest ↓
News Coverage
High Trading Volume
This page (NASDAQ:ATXI) was last updated on 12/1/2022 by MarketBeat.com Staff